Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections

References

• Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Suppl 1):S5–S12. doi:10.1086/49170916323120
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98. doi:10.2146/ajhp08043419106348
   PubMedGoogle Scholar
• Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):365–380. doi:10.1007/s10156-013-0599-423673472
   PubMed Web of Science ®Google Scholar
• Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71(11):3020–3025. doi:10.1093/jac/dkw25427494905
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292. doi:10.1093/cid/cir03421217178
   PubMed Web of Science ®Google Scholar
• Wan M, Walker SAN, Martin E, et al. The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study. BMC Pharmacol Toxicol. 2018;19(1):47. doi:10.1186/s40360-018-0236-z30064515
   PubMed Web of Science ®Google Scholar
• Durham SH, Simmons ML, Mulherin DW, et al. An evaluation of vancomycin dosing for complicated infections in pediatric patients. Hosp Pediatr. 2015;5(5):276–281. doi:10.1542/hpeds.2014-008125934812
   PubMedGoogle Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35–S39. doi:10.1086/49171216323118
   PubMed Web of Science ®Google Scholar
• Sosnin N, Curtis N, Cranswick N, et al. Vancomycin is commonly under-dosed in critically ill children and neonates. Br J Clin Pharmacol. 2019;85(11):2591–2598. doi:10.1111/bcp.1408431378957
   PubMed Web of Science ®Google Scholar
• Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care. 2000;15(1):1–4. doi:10.1053/jcrc.2000.015000110757191
   PubMed Web of Science ®Google Scholar
• Moffett BS, Resendiz K, Morris J, et al. Population pharmacokinetics of vancomycin in the pediatric cardiac surgical population. J Pediatr Pharmacol Ther. 2019;24(2):107–116. doi:10.5863/1551-6776-24.2.10731019403
   PubMedGoogle Scholar
• Giachetto GA, Telechea HM, Speranza N, et al. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children. Pediatr Crit Care Med. 2011;12(6):e250–e254. doi:10.1097/PCC.0b013e3181fe404721057350
   PubMed Web of Science ®Google Scholar
• Avedissian SN, Bradley E, Zhang D, et al. Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients. Pediatr Crit Care Med. 2017;18(9):e388–e394. doi:10.1097/PCC.000000000000122828640009
   PubMed Web of Science ®Google Scholar
• Genuini M, Oualha M, Bouazza N, et al. Achievement of therapeutic vancomycin exposure with continuous infusion in critically ill children. Pediatr Crit Care Med. 2018;19(6):e263–e269. doi:10.1097/PCC.000000000000147429394210
   PubMed Web of Science ®Google Scholar
• Gous AG, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care. 1995;23(6):678–682. doi:10.1177/0310057X95023006038669599
   PubMed Web of Science ®Google Scholar
• Seixas GT, Araujo OR, Silva DC, et al. Vancomycin therapeutic targets and nephrotoxicity in critically ill children with cancer. J Pediatr Hematol Oncol. 2016;38(2):e56–e62. doi:10.1097/MPH.000000000000047026558810
   PubMed Web of Science ®Google Scholar
• Silva DC, Seixas GT, Araujo OR, et al. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients. Braz J Infect Dis. 2012;16(4):361–365. doi:10.1016/j.bjid.2012.06.01122846125
   PubMed Web of Science ®Google Scholar
• Thomas CA, Picone A, Menon S, et al. Empirical vancomycin dosing in pediatric patients with congenital heart disease and the impact of cardiopulmonary bypass on trough concentrations. Pharmacotherapy. 2017;37(11):1341–1346. doi:10.1002/phar.201928833385
   PubMed Web of Science ®Google Scholar
• Janssen EJ, Välitalo PA, Allegaert K, et al. Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling. Antimicrob Agents Chemother. 2015;60(2):1013–1021. doi:10.1128/AAC.01968-1526643337
   PubMed Web of Science ®Google Scholar
• Biagi MJ, Butler DA, Wenzler E. AUC-based monitoring of vancomycin: closing the therapeutic window. J Appl Lab Med. 2019;3(4):743–746. doi:10.1373/jalm.2018.02739131639746
   PubMedGoogle Scholar
• Tseng SH, Lim CP, Chen Q, et al. Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2018;62(4):e01647–17. doi:10.1128/AAC.01647-1729358290
   PubMed Web of Science ®Google Scholar
• Heil EL, Claeys KC, Mynatt RP, et al. Making the change to area under the curve-based vancomycin dosing. Am J Health Syst Pharm. 2018;75(24):1986–1995. doi:10.2146/ajhp18003430333114
   PubMed Web of Science ®Google Scholar
• Kishk OA, Lardieri AB, Heil EL, et al. Vancomycin AUC/MIC and corresponding troughs in a pediatric population. J Pediatr Pharmacol Ther. 2017;22(1):41–47. doi:10.5863/1551-6776-22.1.4128337080
   PubMedGoogle Scholar
• Pediatric Dosing Recommendations. Korean Food and Drug Administration; 2011 Available from: https://nedrug.mfds.go.kr/eBook/access/ecatalog_sp.jsp?catimage=&callmode=¨&Dir=13. Accessed 1129, 2019.
   Google Scholar
• Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21–24.20179794
   PubMedGoogle Scholar
• Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–637. doi:10.1681/ASN.200803028719158356
   PubMed Web of Science ®Google Scholar
• Molitoris BA, Levin A, Warnock DG, et al. Improving outcomes of acute kidney injury: report of an initiative. Nat Clin Pract Nephrol. 2007;3(8):439–442. doi:10.1038/ncpneph055117653122
   PubMedGoogle Scholar
• Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481–1490. doi:10.1086/34035312015695
   PubMed Web of Science ®Google Scholar
• Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260–2266. doi:10.1128/AAC.49.6.2260-2266.200515917519
   PubMed Web of Science ®Google Scholar
• Itani KM, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804–816. doi:10.1016/j.amjsurg.2009.08.04520227056
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138–2144. doi:10.1001/archinte.166.19.213817060545
   PubMedGoogle Scholar
• Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36(11):1418–1423. doi:10.1086/37505712766837
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28(5):398–402. doi:10.1097/INF.0b013e3181906e4019295465
   PubMed Web of Science ®Google Scholar
• Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, et al. Back to basics: understanding drugs in children: pharmacokinetic maturation. Pediatr Rev. 2005;26:321–328. doi:10.1542/pir.26-9-32116140874
   PubMed Web of Science ®Google Scholar
• Suggs DM. Pharmacokinetics in children: history, considerations, and applications. J Am Acad Nurse Pract. 2000;12:236–239. doi:10.1111/j.1745-7599.2000.tb00188.x11930447
   PubMedGoogle Scholar
• Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on pediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077–1097. doi:10.2165/00003088-200645110-0000317048973
   PubMed Web of Science ®Google Scholar
• Elbarbry F. Vancomycin dosing and monitoring: critical evaluation of the current practice. Eur J Drug Metab Pharmacokinet. 2018;43(3):259–268. doi:10.1007/s13318-017-0456-429260505
   PubMed Web of Science ®Google Scholar
• Paediatric, Formulary, Committee. British national formulary for children London: BMJ Group and Pharmaceutical Press; 2016–2017 Available from: http://www.lebpedsoc.org/doc/HIGHLIGHTS%20FROM%20THE%20LITERATURE/bnf%20book.pdf. Accessed 1129, 2019.
   Google Scholar